This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAbout AboutWhy PENBRAYA?Risks of Meningococcal DiseaseGaps in Vaccination CoverageDosing & Recommendations Effectiveness & Safety Effectiveness
& Safety ImmunogenicitySafety ProfileIn Your Practice In Your PracticeSimplified CombinationHow to Transition to PENBRAYAPreparing PENBRAYAResources ResourcesRequest a RepresentativeHealth Plan CoverageMaterialsVideos
Prescribing InformationIndicationsPatient SiteRequest a RepLoading
ACIP recommends PENBRAYA for vaccinating your healthy 16-year-old patients against serogroups A, B, C, W, and Y1PENBRAYA may be used when both MenACWY and MenB are indicated at the same visit1*PENBRAYA may be used when both MenACWY and MenB are indicated at the same visit1*
With PENBRAYA, older adolescents (starting at age 16) can complete their meningococcal vaccination with just 2 injections instead of 31
 The PENBRAYA dosing may work for the schedules of your older adolescent patients who return to their doctor after 6 months on average2§
  • According to the ACIP, when the decision has been made to vaccinate against MenABCWY using PENBRAYA on the basis of SCDM, Trumenba must be used to complete the MenB series. B-component vaccines are not interchangeable by manufacturer. Administration of a B-component vaccine (MenB or MenABCWY) requires that all subsequent B-component vaccine doses be from the same manufacturer1
  • While PENBRAYA was studied and FDA approved for use as a 2-dose series administered 6 months apart and met all endpoints assessing non-inferiority in clinical trials, the ACIP considers many factors in addition to clinical trial results when deciding how to recommend a vaccine1,3
ACIP approved the recommendation for PENBRAYA by majority vote, and it has been adopted by the CDC Director. It was published in MMWR on April 18, 2024. PENBRAYA may be used when both MenACWY and MenB are indicated at the same visit for the following groups: 1) Healthy persons aged 16 to 23 years (routine schedule) when SCDM favors administration of MenB vaccination, and 2) persons aged ≥10 years who are at increased risk of meningococcal disease (eg, because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia).1ACIP recommends routine administration of a MenACWY vaccine for all healthy persons aged 11 to 18 years, with a single dose at age 11 or 12, followed by a booster dose at age 16. ACIP also recommends a 2-dose MenB vaccine series administered 1 to 6 months apart for healthy persons aged 16 to 23 years on the basis of SCDM, with a preferred age range of 16 to 18. Visit ACIP Meningococcal Vaccine Recommendations for additional information, including recommendations for individuals at increased risk.1PENBRAYA and Trumenba are FDA approved for dosing at 0 and 6 months. There is no data supporting the use of Trumenba at an interval of greater than 6 months.3,4Data from a March 2017 US survey of 593 respondents.2ACIP=Advisory Committee on Immunization Practices; MMWR=Morbidity and Mortality Weekly Report;
SCDM=shared clinical decision-making.TRUMENBA® (Meningococcal Group B Vaccine) logo

TRUMENBA

Get information about TRUMENBA (Meningococcal Group B Vaccine)Learn moreLoadingIcon of a document

ACIP Recommendations

See the full ACIP recommendations 

Read recommendationsLoadingIcon of an arrow hitting a target

Immunogenicity

PENBRAYA elicited a robust immune response for serogroups A, B, C, W, and Y See clinical dataLoadingTrumenba logo

TRUMENBA

Get information about TRUMENBA (Meningococcal Group B Vaccine)

Learn moreLoadingCircle icon of document referencing ACIP recommendations

ACIP Recommendations

See the full ACIP recommendations 

Read recommendationsLoadingCircle with target and arrow representing immunogenicity

Immunogenicity

PENBRAYA elicited a robust immune response for serogroups A, B, C, W, and Y 

See clinical dataLoading

References: 1. Collins JP, Crowe JS, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices ― United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345-350. 2. Data on file. Quintiles MS Primary Research Market Study, 2017. 3. PENBRAYA [prescribing information]. New York, NY: Pfizer Inc.; 2023. 4. TRUMENBA [prescribing information]. Philadelphia, PA: Pfizer Inc.; 2021.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PBI-USA-0339
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age 
Important Safety Information
  • Do not administer PENBRAYA or TRUMENBA to individuals with a history of severe allergic reaction (eg, anaphylaxis) to any component of PENBRAYA or TRUMENBA. Appropriate medical treatment used to manage allergic reactions must be available in the event an anaphylactic reaction occurs immediately following administration of PENBRAYA or TRUMENBA
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including PENBRAYA or TRUMENBA. Procedures should be in place to avoid injury from fainting
  • Some individuals with altered immunocompetence may have reduced immune responses to PENBRAYA or TRUMENBA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis groups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENBRAYA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis group B, even if they develop antibodies following vaccination with TRUMENBA
  • Vaccination with PENBRAYA or TRUMENBA may not protect all vaccine recipients
  • Vaccination with PENBRAYA does not substitute for vaccination with a tetanus toxoid–containing vaccine to prevent tetanus
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENBRAYA to individuals with a history of GBS should take into account the expected benefits and potential risks 
  • For PENBRAYA, the most commonly reported (≥15%) solicited adverse reactions after Dose 1 and Dose 2, respectively, were pain at the injection site (89% and 84%), fatigue (52% and 48%), headache (47% and 40%), muscle pain (26% and 23%), injection site redness (26% and 23%), injection site swelling (25% and 24%), joint pain (20% and 18%), and chills (20% and 16%)
  • For TRUMENBA, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)
  • Data are not available on the safety and effectiveness of using TRUMENBA and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • The safety and effectiveness of PENBRAYA or TRUMENBA have not been established in pregnant individuals
     
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for PENBRAYA and full Prescribing Information for TRUMENBA.Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age